logo

Protagonist Therapeutics, Inc (PTGX)



Trade PTGX now with
  Date
  Headline
10/26/2021 7:18:55 AM Protagonist Earns $7.5 Mln Milestone Payment From IL-23 Receptor Collaboration With Janssen
10/11/2021 7:15:23 AM Protagonist Therapeutics Says FDA Removes Clinical Hold On Rusfertide Clinical Development Program
10/4/2021 7:18:11 AM Protagonist Therapeutics Announces Data From Phase 2 Rusfertide Study In Hereditary Hemochromatosis
9/17/2021 7:02:58 AM Protagonist Therapeutics Reports FDA Clinical Hold On Rusfertide Clinical Development Program
9/7/2021 7:20:41 AM Protagonist Therapeutics Appoints Scott Plevy As EVP And Therapeutic Head, Gastroenterology
6/15/2021 9:22:02 PM Protagonist Therapeutics Prices Underwritten Public Offering Of 3.05 Mln Shares At $37.75/shr
6/11/2021 7:14:39 AM Protagonist Therapeutics Announces Updated Results From Ongoing Phase 2 Study Of Rusfertide
6/3/2021 7:06:46 AM Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation For Rusfertide In Polycythemia Vera
5/24/2021 7:05:30 AM Protagonist Therapeutics Announces First Subject Dosed In Phase 1 Study Of Oral IL-23 Receptor Antagonist PN-232
4/27/2021 7:52:54 AM Protagonist Therapeutics Completes Enrollment For Phase 2 Study Of Rusfertide In Polycythemia Vera
3/10/2021 4:05:03 PM Protagonist Therapeutics Q4 Loss/share $0.48 Vs. Loss $0.63 Year Ago
12/16/2020 7:32:34 AM Protagonist Therapeutics Announces First Subject Dosed In Phase 1 Study Of Oral IL-23 Receptor Antagonist PN-235
12/10/2020 11:24:15 PM Protagonist Therapeutics Prices Public Offering Of 4.76 Mln Shares At $21.00/shr
12/10/2020 7:35:48 AM Protagonist Therapeutics Commences Underwritten Public Offering Of $100 Mln Common Shares
12/7/2020 10:08:44 AM Protagonist Therapeutics Reports Results Of Analysis Of Real World Treatment Patterns For Polycythemia Vera